Insurance Denied Chemotherapy — How to Appeal a Cancer Treatment Denial

There are few moments as disorienting as receiving a cancer diagnosis. And there are few moments as cruel as receiving a chemotherapy denial from your insurance company immediately after. You are fighting for your life, and a bureaucracy is getting in the way. This is the reality for thousands of cancer patients every year — and it is a reality that can often be changed through a well-executed appeal. Here is how.

Why Chemotherapy Claims Are Denied

Despite chemotherapy being one of the most established, evidence-backed treatments in medicine, denials happen for reasons that range from technical to outright wrong:

• Off-label use: A chemotherapy drug is approved by the FDA for one cancer type but is being used to treat another, where evidence is strong but the FDA label has not caught up. Many cancer drugs are used off-label because oncology evidence evolves faster than the FDA approval process.
• Not on formulary: Your prescribed drug is not on your plan's drug list, or requires a non-preferred tier exception with higher cost-sharing.
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization delays or denials: Pre-approval was not obtained, denied based on insufficient documentation, or delayed past the treatment window.
• "Experimental" classification: A newer regimen or combination chemotherapy protocol is classified as investigational despite NCCN or ASCO guideline support.
• Clinical trial treatment: If you are enrolled in a clinical trial, insurers sometimes deny chemotherapy costs as research-related.

Federal Protections for Cancer Patients

Important: Most states and many federal regulations require insurers to cover off-label chemotherapy when used in accordance with recognized compendia such as:

• National Comprehensive Cancer Network (NCCN) Drug & Biologics Compendium
• Micromedex
• American Hospital Formulary Service Drug Information (AHFS-DI)

The Social Security Act requires Medicare to cover off-label chemotherapy appearing in these compendia. Many state laws mirror this for commercial insurance. If your denial is based on off-label use, cite your state's chemotherapy coverage law and the relevant compendium listing in your appeal.

Clinical Guidelines That Support Your Case

The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) are the primary clinical guideline bodies for oncology:

• NCCN guidelines categorize treatment recommendations as Category 1 (highest evidence), Category 2A, and 2B. Category 1 and 2A recommendations carry strong evidence and wide acceptance.
• ASCO clinical practice guidelines cover specific cancer types and provide evidence-based treatment frameworks.
• If your regimen is listed in NCCN guidelines for your cancer type and stage, that is powerful grounds for appeal.

Constructing the Appeal

Time is particularly critical in oncology. Appeals should be filed immediately. Include:

1. Oncologist's letter of medical necessity — specific cancer diagnosis, stage, histology, relevant biomarkers (e.g., KRAS, EGFR, HER2, PD-L1), and clinical rationale for the specific chemotherapy regimen.
2. Pathology report confirming diagnosis and relevant molecular markers.
3. NCCN guideline reference showing the requested regimen is a guideline-concordant treatment for your cancer type and stage.
4. Compendium listing if the issue is off-label use.
5. Documentation of prior treatment lines if this is a second or third-line therapy.
6. Statement of urgency from your oncologist documenting why delay of treatment is medically harmful.

Requesting Expedited Appeal

For chemotherapy specifically, always request an expedited appeal. Your oncologist's documentation that treatment delay is medically dangerous — because cancer progression occurs during delay — qualifies the case for 72-hour review. Do not wait for standard appeal timelines when treatment is urgent.

External Independent Review: Complete Guide" class="auto-link">External Review Is Powerful for Oncology

Independent external reviewers for cancer treatment cases are typically oncologists who apply NCCN guidelines, not cost-focused criteria. External review overturn rates for oncology cases are meaningful, particularly when the appeal documents guideline-concordant care.

If Your Insurer Says "Experimental"

If your chemotherapy is denied as experimental or investigational, attach documentation showing:

• Published peer-reviewed clinical trial data supporting the regimen
• NCCN or ASCO guideline listing
• FDA approval status

If none of these exist, discuss with your oncologist whether the treatment meets the criteria for insurance-covered clinical trial participation under the ACA's clinical trial coverage provisions.

Advocacy Resources

• American Cancer Society (cancer.org) — insurance navigation line: 1-800-227-2345
• Cancer Care (cancercare.org) — free counseling and financial assistance
• NCCN Patient Resources (nccn.org) — guideline summaries for patients
• Patient Advocate Foundation (patientadvocate.org) — oncology case managers

Fight Back With ClaimBack

You should be spending your energy on treatment, not bureaucracy. ClaimBack helps cancer patients and their families build urgent, evidence-based chemotherapy appeals that cite the clinical standards insurers are supposed to follow.

Start your appeal today at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal — Know the Difference